Retinal texture biomarkers may help to discriminate between Alzheimer's, Parkinson's, and healthy controls

PLoS One. 2019 Jun 21;14(6):e0218826. doi: 10.1371/journal.pone.0218826. eCollection 2019.

Abstract

A top priority in biomarker development for Alzheimer's disease (AD) and Parkinson's disease (PD) is the focus on early diagnosis, where the use of the retina is a promising avenue of research. We computed fundus images from optical coherence tomography (OCT) data and analysed the structural arrangement of the retinal tissue using texture metrics. We built clinical class classification models to distinguish between healthy controls (HC), AD, and PD, using machine learning (support vector machines). Median sensitivity is 88.7%, 79.5% and 77.8%, for HC, AD, and PD eyes, respectively. When the same subject has the same classification for both eyes, 94.4% (median) of the classifications are correct. A significant amount of information discriminating between multiple neurodegenerative states is conveyed by OCT imaging of the human retina, even when differences in thickness are not yet present. This technique may allow for simultaneously diagnosing Alzheimer's and Parkinson's diseases.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / diagnosis*
  • Alzheimer Disease / pathology
  • Biomarkers* / analysis
  • Case-Control Studies
  • Diagnosis, Differential
  • Diagnostic Techniques, Neurological*
  • Diagnostic Techniques, Ophthalmological
  • Disease Progression
  • Early Diagnosis
  • Female
  • Fundus Oculi
  • Health
  • Humans
  • Male
  • Middle Aged
  • Nerve Fibers / pathology
  • Parkinson Disease / diagnosis*
  • Parkinson Disease / pathology
  • Predictive Value of Tests
  • Retina / diagnostic imaging*
  • Retina / pathology*
  • Support Vector Machine
  • Tomography, Optical Coherence

Substances

  • Biomarkers

Grants and funding

Authors AFA, MCB, RB were supported by: The changing brain in Alzheimer’s disease: is the retina a reliable mirror of disease onset and progression? Mantero Belard Award - Santa Casa Awards – Neurosciences (3rd edition), MB-1049-2015 (Funder name: Santa Casa da Misericórdia de Lisboa Funder URL: http://www.scml.pt/). Authors AN, CJ, AFA, MCB, RB were supported by: BIGDATAIMAGE - From computational modelling and clinical research to the development of neuroimaging big data platforms for discovery of novel biomarker, CENTRO-01-0145-FEDER-000016 (Funder name: Comissão de Coordenação e Desenvolvimento Regional do Centro Funder URL: http://www.ccdrc.pt/). Authors AN, CJ, IS, AFA, MCB, RB were supported by: PEst-UID/NEU/04539/2013, FEDER-COMPETE (POCI-01-0145-FEDER-007440 and POCI01-0145-FEDER-016428) (Funder name: Fundação para a Ciência e Tecnologia Funder URL: https://www.fct.pt/). Authors AFA, MCB were supported by: CENTRO-01-0145-FEDER-000008: BrainHealth 2020 (Funder name: Centro 2020 Funder URL: http://www.centro.portugal2020.pt/).